Oscotec Inc. announced topline results for Phase 2 trial evaluating the efficacy, safety and tolerability of cevidoplenib (SYK inhibitor) in immune thrombocytopenia (ITP) patients who have failed to respond or relapsed after prior therapy. Cevidoplenib was evaluated in a 61-participant randomized, placebo-controlled trial to access its efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of select (200 mg BID and 400 mg BID) doses in ITP patients with a platelet count <30,000/µL. The study duration was 20 weeks per subject, which consists of up to 4 weeks of screening period, 12 weeks of treatment period, and 4 weeks of follow-up period. Primary endpoint of this study is the platelet response rate defined as platelet counts (PLTs) =30,000/µL and doubling the baseline.

The response rate for the participants who were treated with cevidoplenib at the higher dose (400 mg) was 63.6% compared to 33.3% on placebo with p-value of 0.151. In the secondary endpoints, 50.0% of the participants on the higher dose (400 mg) achieved 2 or more consecutive PLTs of =30,000/µL compared to 8.3% on placebo (p = 0.015) and 40.9% achieved PLT =50,000/µL vs. 8.3% on placebo (p = 0.055).

It should be noted that these secondary endpoints were more comparable to the ones used as the primary endpoints in the clinical trials of the competitors. Oscotec is planning to present detailed results at European Hematology Association in June.